Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
[Summary]GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS (edaravone) and IV RADIC
Shionogi Receives Approval in Japan to Manufacture and Market ZURZUVAE Capsules 30 mg for the Treatment of Major Depressive Disorder
Notice regarding Completion of Succession of Japan Tobacco Inc.’s Pharmaceutical Business through Simplified Absorption-Type Company Split
(Corrections / Correction of Numerical Data) Corrections to the Consolidated Financial Results for the Second Quarter of Fiscal Year 2025 (IFRS)
Corporate Governance Report
Action to Implement Management that is Conscious of Cost of Capital and Stock Price
2nd Quarter of Fiscal 2025 Financial Results
Shionogi, Net Income Forecast for the Fiscal Year Revised Upward by 4%, Highest in Three Terms
Notice Regarding Absorption-type merger of Shionogi Pharma Co., Ltd.
Supplemental material for financial results for the 2nd quarter
Consolidated Financial Results for the second Quarter of Fiscal Year 2025 (IFRS)
Notice Regarding the Execution of an Absorption-Type Company Split Agreement (Simplified Absorption-Type Split) for the Succession of Business
FDA Accepts Shionogi’s Ensitrelvir NDA for Review as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
Notice of Acquisition of TORII PHARMACEUTICAL CO., LTD. as a Wholly-Owned Subsidiary
Supplemental material for financial results for the 1st quarter of fiscal year 2025
1st Quarter of Fiscal 2025 Financial Results
Consolidated Financial Results for the First Quarter of Fiscal Year 2025 (IFRS)
Shionogi, Apr-Jun (1Q) Net Income Increases by 28%
ViiV Healthcare’s Presentation on the VOLITION Study of Long-Acting Injectable Cabenuva in HIV Treatment